6 results about "Hypercalcinemia" patented technology

This disclosure relates to antibodies that specifically bind to parathyroid hormone-related protein (PTHrP). Immunoconjugates, nucleic acids, vectors, cells, and compositions comprising said antibodies are also provided. The antibodies, immunoconjugates, nucleic acids, vectors, cells, and compositions can be used for the diagnosis and treatment of diseases, particularly cancer and / or hypercalcemia.

Disclosed are peptide-fatty acid conjugates, pharmaceutical compositions containing them, and methods of their medical use in the treatment of, e.g., a disease or condition associated with the PTHR1 signaling overactivity (e.g., hypercalcemia, hypophosphatemia, hyperparathyroidism, or Jansen's metaphyseal chondrodysplasia) or deficiency (e.g., hypoparathyroidism, hyperphosphatemia, osteoporosis, fracture repair, osteomalacia, arthritis, thrombocytopenia, or chronic kidney disease).

The present disclosure relates to an animal food composition including from about 0.3 g / Mcal to about 0.8 g / Mcal of magnesium or a salt thereof, for use in a method for treating and / or preventing a mineral bone disorder, especially mineral bone disorder associated with hypercalcemia, in a companion animal that is affected by, or at risk to be affected by, a kidney dysfunction.

Abstract The present invention relates to pharmaceutical compositions comprising a controlled-release PTH compound or a pharmaceutically acceptable salt, hydrate, or solvate thereof, for use in a method of treating, controlling, delaying or preventing a condition which can be treated, controlled, delayed or prevented with PTH, wherein the pharmaceutical composition comprising the controlled-release PTH compound is administered in accordance with a dosage regimen in which dose adjustment in response to hypocalcemia or hypercalcemia is performed in increments of no more than 25%. This data, for application number 2023202402, is current as of 2024-12-02 22:50 AEDT Abstract The present invention relates to pharmaceutical compositions comprising a controlled-release PTH compound or a pharmaceutically acceptable salt, hydrate, or solvate thereof, for use in a method of treating, controlling, delaying or preventing a condition which can be treated, controlled, delayed or prevented with PTH, wherein the pharmaceutical composition comprising the controlled-release PTH compound is administered in accordance with a dosage regimen in which dose adjustment in response to hypocalcemia or hypercalcemia is performed in increments of no more than 25%. This data, for application number 2023202402, is current as of 2024-12-02 22:50 AEDT 20 24 27 06 32 03 D ec 2 02 4 0 3 D e c 2 0 2 4 2 0 2 4 2 7 0 6 3 2

The present invention relates to pharmaceutical compositions comprising a controlled-release PTH compound or a pharmaceutically acceptable salt, hydrate, or solvate thereof, for use in a method of treating, controlling, delaying or preventing a condition which can be treated, controlled, delayed or prevented with PTH, wherein the pharmaceutical composition comprising the controlled-release PTH compound is administered in accordance with a dosage regimen in which dose adjustment in response to hypocalcemia or hypercalcemia is performed in increments of no more than 25%.

This invention provides a composition comprising an LSD1 inhibitor and 1,25(OH)2D3 and its application in the treatment of acute monocytic leukemia. The composition provided by this invention can induce AML-M5 cell differentiation, achieving the therapeutic effect on acute monocytic leukemia while avoiding the side effect of hypercalcemia caused by high doses of 1,25(OH)2D3.